Read more
This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.
List of contents
Part 1. Introduction.- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review).- Part 2. Impact of complement on diabetic disease.- 2. Complement and Complement Regulatory Proteins in Diabetes.- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation.- 3. Development of adiponectin receptor C terminal fragment bioassays.- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor.- 5. Cell & biological models for the C terminal fragment of adiponectin receptor.- 6. C-Terminal fragment of adiponectin receptor clinical correlations.- Part 4. Uristatin assay for prediction of renal and other clinical events.- 7. Uristatin immunoassay usage in glomerular nephritis assessment.- 8. Acute Response of Uristatin in Surgery.- 9. Cardiovascular and metabolic syndrome impact on uristatin.- 10. Uristatin anti-inflammatory cellular signaling.- Part 5. Summary.- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review).
About the author
Dr. Pugia is the Principal Key Expert at Siemens Healthcare Diagnostics in the Strategic Innovation Group in Strategy and Business Development. Over the last 25 years, he has held various Research & Development positions and been involved in over 20 new products in the MULTISTIX, CLINITEK, CLINITEST and DCA brands for urinalysis and professional diabetes as well as other business units. He has a Ph.D. in Chemistry from Texas Tech University (1986), a B.S. in Chemistry from Clarkson University (1982) and was Visiting Scholar at the University of Notre Dame (2004-2008). His research areas are proteomic biomarker discovery and treatment in inflammatory immune diseases in the field of endocrinology and onocology. He has 256 patents world wide, 48 full-length manuscripts and 6 book chapters in a wide variety of chemistry disciplines. In 2009, he was a Siemens Inventor of the Year, he was the first Al Free Memorial Lecturer in 2001 and in 2002 was awarded the Samual Natelson Award by the American Association for Clinical Chemistry. He has also been awarded nine corporate Science and Technology Awards while in Bayer and Miles Diagnostics.
